Evaxion is please to announce the successful conclusion of a series of large non-rodent animal infection studies, testing antigens from Evaxion’s preclinical EVX-B1 vaccine candidate against Staphylococcus aureus (S. aureus).

At our recent Research & Development (R&D) Day, we provided insights into our AI-Immunology™ platform for fast and effective vaccine target discovery, design, and development. Take a look at the in-depth presentations captured in a series of videos. 

Evaxion announced the pricing of a public offering of an aggregate of 3,750,000 of its American Depositary Shares (“ADSs”) (or pre-funded warrants in lieu thereof) and warrants to purchase up to 3,750,000 ADSs at a combined public offering price of $4.00 per ADS (or pre-funded warrant in lieu thereof) and accompanying warrant.

Evaxion announced a collaboration with Afrigen Biologics (Afrigen).

Evaxion announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen.

In this study, we demonstrate how the addition of an antigen-presenting cell (APC) binding molecule to DNA-encoded cancer neoepitopes improves neoepitope-specific T-cell responses and the anti-tumor efficacy of plasmid DNA vaccines.

Evaxion has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDEN.

Evaxion has hired a new Chief Executive Officer (“CEO”) to accelerate the strategic development and execution of the vast business opportunities at hand after having matured the Company’s AI platforms over the past 15 years.

With autumn on the horizon, Evaxion is poised to take center stage at the season's pivotal conferences. We look forward to presenting our business, engaging with fellow biotech innovators, and drawing inspiration. Click here to learn more about all our upcoming conferences.